James Quigley
Stock Analyst at Goldman Sachs
(0.50)
# 3,922
Out of 4,847 analysts
22
Total ratings
50%
Success rate
-25.02%
Average return
Main Sectors:
Stocks Rated by James Quigley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KYMR Kymera Therapeutics | Upgrades: Overweight | $49 → $79 | $43.13 | +83.17% | 6 | Jun 3, 2025 | |
| SNY Sanofi | Initiates: Neutral | $65 | $49.19 | +32.14% | 1 | Mar 21, 2025 | |
| NVS Novartis AG | Downgrades: Neutral | $119 → $121 | $116.70 | +3.68% | 1 | Sep 5, 2024 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $8.30 | +26.51% | 1 | Dec 5, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $29.21 | +36.96% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $3.98 | +302.01% | 3 | Jun 23, 2023 |
Kymera Therapeutics
Jun 3, 2025
Upgrades: Overweight
Price Target: $49 → $79
Current: $43.13
Upside: +83.17%
Sanofi
Mar 21, 2025
Initiates: Neutral
Price Target: $65
Current: $49.19
Upside: +32.14%
Novartis AG
Sep 5, 2024
Downgrades: Neutral
Price Target: $119 → $121
Current: $116.70
Upside: +3.68%
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $8.30
Upside: +26.51%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $29.21
Upside: +36.96%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $3.98
Upside: +302.01%